= Solution
\b[A <DNA library> synthesis method determines which variants can be reached, how often they are sampled, and which evolutionary paths remain available.] The nominal number of <DNA> molecules is less informative than the distribution of functional <amino acid> sequences presented to the assay. <directed evolution> couples diversification to a <genotype-phenotype linkage>, screening or selection, and recovery of successful genotypes. Construction controls the accessible moves through <protein sequence space> and therefore interacts with assay capacity, starting sequence and <epistasis>; it is part of the evolutionary strategy rather than an interchangeable preliminary step.
<error-prone PCR> explores substitutions throughout an existing <gene> without requiring prior structural knowledge. <R. Craig Cadwell> and <Gerald F. Joyce> demonstrated controlled PCR <mutagenesis> using a ribozyme sequence, establishing a general route for generating variant templates.<Randomization of genes by PCR mutagenesis by R. Craig Cadwell and Gerald F. Joyce>[Altered PCR fidelity and distribution of mutations]{ref} For <protein> evolution, polymerase preferences, sequence context and the <genetic code> make <amino acid> changes uneven: a substitution requiring two nucleotide changes is less accessible than a single-base neighbour. Increasing the <mutation> rate reaches more distant variants but often increases inactive products and makes attribution difficult. Insertions and deletions can also change the <reading frame>. Existing useful sequence combinations are usually retained at a low <mutation load>, but extensive remodelling is hard to reach by successive selections if intermediate genotypes are deleterious.
An idealized <Poisson distribution> with mean <mutation> count $\lambda$ makes this trade-off quantitative:
$$
P(m)=e^{-\lambda}\frac{\lambda^m}{m!}.
$$
At $\lambda=1$, about 37% of molecules have no change and 37% have one; at $\lambda=3$, only about 5% are unchanged and about 80% contain two or more changes. This is a planning model, not a guarantee that a real PCR <DNA library> is unbiased or independent at every site. Early PCR events can generate many related descendants, and the number of nucleotide <mutations> is not the number of distinct <amino acid> substitutions.
Oligonucleotide-directed <saturation mutagenesis> concentrates the assay budget at specified sites, for example an <active site> pocket or an interface. <degenerate codons> are convenient but biased. <NNK> and <NNS> each encode 32 <codons>, including one <stop codon>, with unequal multiplicities for different <amino acids>. At $k$ independently synthesized sites the ideal fraction lacking these introduced stops is $(31/32)^k$, even before assembly errors or deleterious substitutions. A <DNA library> of $20^k$ <amino acid> combinations can therefore contain many redundant <codons> and uneven representation. Trinucleotide mixtures assemble complete chosen <codons> and can exclude stops, equalize <amino acid> sampling, or deliberately favour a chemically relevant subset. <Bernhard Virnekas> and colleagues developed such <trinucleotide phosphoramidites> for mixed-oligonucleotide synthesis.<Trinucleotide phosphoramidites: ideal reagents for the synthesis of mixed oligonucleotides for random mutagenesis by Bernhard Virnekas and others>[Whole-codon synthesis for controlled amino-acid mixtures]{ref} Controlled diversity is valuable, but restricting sites according to an incomplete structural model can miss beneficial remote <mutations>.
<DNA shuffling> offers a different move: <genetic recombination> among already useful or homologous sequences. Random fragmentation followed by annealing and polymerase extension reconstructs <genes> from overlapping parental fragments. <Willem P. C. Stemmer> demonstrated reassembly and <genetic recombination>, including chimeric sequences, providing a practical route to combine sequence blocks rather than relying only on isolated substitutions.<DNA shuffling by random fragmentation and reassembly: in vitro recombination for molecular evolution by Willem P. C. Stemmer>[Fragmentation, gene reassembly and recombinant products]{ref} This can unite improvements acquired in separate lineages and remove unwanted changes by <genetic recombination> with a parent. However, crossovers favour compatible homologous regions, closely related parents may add little diversity, and breaking a coadapted combination can lower fitness. Positive or negative <epistasis> means the fitness of a recombinant cannot be predicted by adding the effects of its parental substitutions.
Designed synthetic <genes> and pooled oligonucleotide assembly can specify more extensive combinations, deletions, insertions or carefully chosen paths between distant sequences. This can test combinations inaccessible to single-base steps and explicitly balance beneficial candidates against exploratory variants. The cost is that synthesis, assembly and amplification introduce errors and abundance differences; a designed sequence is not necessarily a correctly constructed or well represented molecule. Long constructs may need assembly from overlapping fragments, and different fragment yields can skew the <DNA library>. A finite screen also prevents exhaustive exploration simply by purchasing a larger pool.
Sampling makes these differences concrete. If a target variant has <DNA library> frequency $p$, screening $n$ independent clones finds it with probability
$$
P(\mathrm{hit})=1-(1-p)^n.
$$
For $M$ equally frequent variants, the expected number of distinct variants observed is $M[1-(1-1/M)^n]$. Screening 1000 clones from a uniform two-site <amino acid> <DNA library> with $M=400$ visits about 92% of the variants on average; from a three-site <DNA library> with $M=8000$, it visits only about 12%. These are expected fractions, not probabilities that every variant has been sampled. Roughly $3/p$ clones give a 95% chance of observing one specified rare variant when $p$ is small. Synthesis bias and clonal duplication can make the effective coverage substantially worse.
The course of evolution should therefore be planned alongside screening. Begin with a <mutation load> or site set that the assay can actually cover, sequence the unselected <DNA library> to measure <mutation> spectra, stop frequency, parental carry-over and representation, and compare those frequencies with selected output. Use matched expression conditions and retain <genotype-phenotype linkage>: selection for growth, expression or display can otherwise enrich a variant that performs poorly as a purified <enzyme>. Reconstruct hits independently, sequence the complete <gene>, measure soluble <protein> and validate the desired activity or specificity at controlled <protein> concentration. Include parental and known inactive controls and, where relevant, more than one <substrate> or environmental condition. Subsequent rounds can recombine verified hits, adjust <mutation load> or target sites suggested by the first round. \b[The best synthesis method maximizes useful, testable diversity under the assay budget and enables appropriate paths through the <fitness landscape>; maximal random diversity alone is not the objective.]
Back to article page
